semaglutide coming off Woman shares journey of weight loss and gain after using Stopping GLP-1s Safely: What to

Inspiration for a new year in 2026.

Dose Chart Home

Digital weight loss company Noom has entered the evolving GLP-1 medication landscape with the launch of its Noom Microdose GLP-1Rx Program, offering members personalized microdoses of GLP-1 medications combined with behavioral coaching and clinical support

Among people with pre-existing SUDs, initiation of GLP-1 receptor agonists was associated with reduced risk of SUD related emergency department visits (0.69 (0.61 to 0.78), NRD 8.92 (11.59 to 6.25)), SUD related hospital admissions (0.74 (0.65 to 0.85), NRD 6.23 (8.73 to 3.74)), and SUD related mortality (0.50 (0.32 to 0.79), NRD 1.52 (2.32 to 0.72)), and drug overdose (0.61 (0.42 to 0.88), NRD 1.49 (2.43 to 0.55)) and suicidal ideation or attempt (0.75 (0.67 to 0.83), NRD 9.95 (13.14 to 6.77))

semaglutide effetti muscolo scheletrici diabete peso sarcopenia Firenze insulino resistenza turnover osseo fragilit fratture cadute rischio

If you've been hesitant about weight-loss injections, or simply want a more convenient route to clinically-backed treatment, this approval changes the landscape dramatically